1,035 results on '"Rispens, Theo"'
Search Results
2. Immunogenicity of Therapeutic Proteins
3. The unique properties of IgG4 and its roles in health and disease
4. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy
5. Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study
6. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication
7. Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy
8. Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study
9. mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses
10. Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling
11. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
12. A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis
13. Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
14. Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
15. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases
16. The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
17. Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial
18. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
19. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
20. The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
21. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
22. Human IgE does not bind to human FcRn
23. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
24. Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report
25. P137 Concentrations of subcutaneously administered belimumab in human breast milk in a woman with systemic lupus erythematosus: a case report
26. Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection
27. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
28. Early model-based precision-dosing at home to guide adalimumab therapy
29. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis
30. Impact of structural modifications of IgG antibodies on effector functions
31. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
32. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study
33. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment.
34. Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.
35. Immunogenicity of Therapeutic Proteins
36. Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies
37. CD5L is a canonical component of circulatory IgM
38. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
39. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
40. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod
41. Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic–Pharmacodynamic Modeling
42. The Influence of Human IgG Subclass and Allotype on Complement Activation
43. Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination
44. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
45. Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load
46. Belimumab concentration measurements using a homologous anti-idiotype immunoassay
47. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study
48. Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease.
49. Longitudinal increase of humoral responses after four SARS-CoV-2 vaccinations and infection in MS patients on fingolimod.
50. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.